X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (33) 33
index medicus (30) 30
female (25) 25
hematology (25) 25
male (24) 24
middle aged (22) 22
adult (20) 20
aged (20) 20
risk (12) 12
anticoagulants - therapeutic use (11) 11
aged, 80 and over (10) 10
risk factors (9) 9
treatment outcome (9) 9
diagnosis (8) 8
prospective studies (8) 8
recurrence (8) 8
therapy (8) 8
thrombosis (8) 8
hematology, oncology and palliative medicine (7) 7
anticoagulants (6) 6
cancer (6) 6
care and treatment (6) 6
incidence (6) 6
peripheral vascular disease (6) 6
pulmonary-embolism (6) 6
time factors (6) 6
venous thrombosis (6) 6
venous thrombosis - drug therapy (6) 6
abridged index medicus (5) 5
analysis (5) 5
anticoagulants - administration & dosage (5) 5
anticoagulants - adverse effects (5) 5
chronic myeloid leukemia (5) 5
cohort studies (5) 5
confidence intervals (5) 5
follow-up studies (5) 5
hemorrhage - chemically induced (5) 5
heparin, low-molecular-weight - therapeutic use (5) 5
neoplasms - complications (5) 5
oncology (5) 5
recurrent venous thromboembolism (5) 5
1st episode (4) 4
adolescent (4) 4
d-dimer (4) 4
dosage and administration (4) 4
drug administration schedule (4) 4
drug therapy (4) 4
hemic and lymphatic diseases (4) 4
imatinib (4) 4
leukemia (4) 4
mortality (4) 4
myeloid leukemia (4) 4
neoplasms - blood (4) 4
prevention (4) 4
retrospective studies (4) 4
rituximab (4) 4
settore med/15 - malattie del sangue (4) 4
severity of illness index (4) 4
survival (4) 4
tyrosine (4) 4
ultrasonography (4) 4
venous thrombosis - complications (4) 4
vitamin k - antagonists & inhibitors (4) 4
warfarin - therapeutic use (4) 4
young adult (4) 4
adamts13 protein (3) 3
antibodies, monoclonal, murine-derived - therapeutic use (3) 3
anticoagulation (3) 3
blood clot (3) 3
disease (3) 3
expression (3) 3
fibrin fibrinogen degradation products - analysis (3) 3
genetics & heredity (3) 3
heart valve prosthesis - adverse effects (3) 3
kinases (3) 3
management (3) 3
molecular-weight heparin (3) 3
neoplasms - drug therapy (3) 3
nilotinib (3) 3
patients (3) 3
prevalence (3) 3
prognosis (3) 3
protein-tyrosine kinase (3) 3
pulmonary embolism - diagnosis (3) 3
pulmonary embolism - drug therapy (3) 3
pulmonary embolism - etiology (3) 3
registries (3) 3
sunlight (3) 3
surgery (3) 3
thromboembolism (3) 3
thromboembolism - epidemiology (3) 3
thromboembolism - etiology (3) 3
thromboembolism - prevention & control (3) 3
thrombophilia - etiology (3) 3
titanium dioxide (3) 3
venous thromboembolism (3) 3
venous thromboembolism - drug therapy (3) 3
venous thrombosis - diagnostic imaging (3) 3
venous thrombosis - pathology (3) 3
venous thrombosis - prevention & control (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLOS ONE, ISSN 1932-6203, 07/2019, Volume 14, Issue 7, p. e0218444
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5122 - 5122
Abstract Introduction Chronic myeloid leukemia (CML) is a stem cell disease characterized by the constitutive activity of the oncoprotein BCR-ABL that... 
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2017, Volume 23, Issue 23, pp. 7189 - 7198
Purpose: The approval of second-generation tyrosine kinase inhibitors (TKIs) for the first-line treatment of chronic myeloid leukemia (CML) has generated an... 
Tyrosine | BCR protein | Imatinib | Transformation | Myeloid leukemia | Leukemia | Chronic myeloid leukemia | Kinases | Patients | Intolerance | Experimental design | Diagnosis | Protein-tyrosine kinase | Cancer
Journal Article
Cancer Biomarkers, ISSN 1574-0153, 2017, Volume 21, Issue 1, pp. 41 - 53
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5435 - 5435
Abstract Background Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disorder which molecular base is represented by the bcr-abl fusion gene,... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5118 - 5118
Abstract Background Targeted therapy with Tyrosine-Kinase-Inhibitors (TKIs) totally modified the course of treatment of Chronic Myeloid Leukemia (CML). The... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1652 - 1652
Background. Ponatinib is a third-generation tyrosine kinase inhibitor indicated for adult patients with resistant or intolerant chronic phase (CP), accelerated... 
Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2012, Volume 87, Issue 4, pp. 388 - 391
Journal Article
American Journal of Hematology, ISSN 0361-8609, 11/2011, Volume 86, Issue 11, pp. 914 - 917
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 5178 - 5178
Abstract This study aimed to determine the gene expression profiling (GEP) of bone marrow (BM) CD34+/lin- cells of CML patients at diagnosis and after... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 5177 - 5177
Abstract Chronic myeloid leukemia (CML) is a disease of stemming from genetic damage to a hematopoietic stem cell. Despite nilotinib being a very effective... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 3645 - 3645
Abstract The study analyzed 30 chronic phase CML patients at diagnosis and at 3, 6 and 12 months of first-line nilotinib treatment. As optimal molecular... 
Journal Article
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 12/2017, Volume 23, Issue 23, pp. 7189 - 7198
Purpose: The approval of second-generation tyrosine kinase inhibitors (TKIs) for the first-line treatment of chronic myeloid leukemia (CML) has generated an... 
TYROSINE KINASE INHIBITORS | CHRONIC MYELOGENOUS LEUKEMIA | SURVIVAL | THERAPY | ONCOLOGY | BCR-ABL | FOLLOW-UP | MOLECULAR RESPONSE | OUTCOMES | DASATINIB | CHRONIC MYELOID-LEUKEMIA
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.